Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2014

View Archived Issues

U.S. researchers prepare new anti-B7-H5 antibodies

Biscayne Pharmaceuticals present data on novel GHRH antagonist

Ossianix extends research collaboration with Lundbeck for CNS therapeutics

Ascendis reports interim data from phase II pediatric study of TransCon Growth Hormone

Promising data presented on novel drug for the treatment of pyruvate kinase deficiency

Bone Therapeutics' phase I/IIa trial of Allob in delayed-union fractures recommended to continue

OncoSynergy forms agreement with CMC Biologics

MicroRNAs identified as potential markers of epilepsy

Antiangiogenic gene therapy evaluated in phase I/II glioblastoma study

Cardiac biomarkers have prognostic significance in coronary artery disease

Midafresa intravenous injection 0.1% for status epilepticus launched in Japan

Emergent BioSolutions acquires portfolio of broad-spectrum antibiotics

USAID awards funding to DNDi for onchocerciasis and elephantiasis

Tetraphase's eravacycline is noninferior to ertapenem in cIAI

Amunix confirms option exercise by Eli Lilly for XTEN product

Cara Therapeutics' CR-845 safe and well tolerated in patients undergoing hemodialysis

Cerulean initiates phase I/IIa trial of CRLX-301 docetaxel-bearing nanoparticles

Preclinical characterization of a novel dual orexin receptor antagonist

Bayer files BLA for BAY-81-8973 for treatment of hemophilia A

Janssen licenses recombinant hyaluronidase technology from Halozyme

Olaparib receives E.U. approval for BRCA-mutated ovarian cancer

Lilly divulges dopamine D1 receptor PAMs

Cellectis and bluebird bio report development of HIV treatment

Janssen Pharmaceutica prepares new mGlu2 receptor modulators

Abraxane approved for additional indication of unresectable pancreatic cancer in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...